Bendroflumethiazide

Antihypertensive diuretic drug
  • Risk neonatal thrombocytopenia in 3rd trimester[1]
Routes of
administrationOralATC code
  • C03AA01 (WHO)
Legal statusLegal status
  • UK: POM (Prescription only)
Pharmacokinetic dataBioavailability100%Protein binding96%MetabolismextensiveElimination half-life3-4 hours[2]Identifiers
  • 3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide
CAS Number
  • 73-48-3 checkY
PubChem CID
  • 2315
IUPHAR/BPS
  • 7122
DrugBank
  • DB00436 checkY
ChemSpider
  • 2225 checkY
UNII
  • 5Q52X6ICJI
KEGG
  • D00650 checkY
ChEBI
  • CHEBI:3013 checkY
ChEMBL
  • ChEMBL1684 checkY
CompTox Dashboard (EPA)
  • DTXSID5022647 Edit this at Wikidata
ECHA InfoCard100.000.728 Edit this at WikidataChemical and physical dataFormulaC15H14F3N3O4S2Molar mass421.41 g·mol−13D model (JSmol)
  • Interactive image
  • FC(F)(F)c3c(cc1c(NC(NS1(=O)=O)Cc2ccccc2)c3)S(=O)(=O)N
  • InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23) checkY
  • Key:HDWIHXWEUNVBIY-UHFFFAOYSA-N checkY
  (verify)

Bendroflumethiazide, formerly bendrofluazide, trade name Aprinox, is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

It was patented in 1958 and approved for medical use in 1960.[3]

Adverse effects

Common adverse effects:[4]

Rare adverse effects:[5]

Alcohol

Bendroflumethiazide is known to have an adverse interaction with alcohol. It is advised that those using this diuretic should abstain from alcohol consumption during use, as it is possible to experience a sudden drop in blood pressure, especially if standing up (an effect known as orthostatic hypotension).

Other considerations

Bendroflumethiazide should not be used by pregnant women, or women who have just given birth. Due to the nature of the medication, it is possible for it to pass into the breast milk and consequently to the child. It is also known that bendroflumethiazide suppresses the production of breast milk. Pregnant or lactating women with hypertension may need to discuss with their prescriber as to which alternative treatment may be more suitable. Bendroflumethiazide may also impair the user's motor skills, therefore it is important to be aware of its effects and to take caution when operating machinery of driving.[4]

References

  1. ^ BNF 45 March 2003
  2. ^ Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 456. ISBN 9783527607495.
  4. ^ a b "Bendroflumethiazide". NHS. 29 August 2018. Retrieved 2018-09-29.
  5. ^ "Bendroflumethiazide Side Effects". Drugs.com. Retrieved 2018-09-29.
  • v
  • t
  • e
Sulfonamides
(and etacrynic acid)
CA inhibitors (at PT)
Loop (Na-K-Cl at AL)
Thiazides (Na-Cl at DCT,
Calcium-sparing)
Thiazide-likes (primarily DCT)
Potassium-sparing (at CD)
ESC blockers
Aldosterone antagonists
Osmotic diuretics (PT, DL)
Vasopressin receptor inhibitors
(DCT and CD)
Other
Combination products